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Adjunctive medical therapy during primary 
percutaneous coronary intervention (PPCI) is 
based on anticoagulation and antiplatelet drugs. Ad-
ditionally, the glycoprotein IIb/IIIa inhibitor (GPI) 
abciximab has been shown to reduce infarct size in 
some clinical trials [1]. However, the role of intra-
coronary fibrinolysis has not been well established 
during PPCI. We sought to explore the hypothesis 
that a locally administered fibrinolytic could be 
more effective in dissolving coronary thrombus 
at the macro and microvasculature than adding 
a third antiplatelet drug in patients already receiving 
double antiplatelet therapy, and therefore improve 
myocardial perfusion and left ventricular function. 
The present study involved conducting 
a phase-III, single-center, prospective, randomized 
controlled trial, in which patients with acute an-
terior ST-segment elevation myocardial infarc-
tion (STEMI) and a coronary flow-limiting lesion 
(Thombolysis In Myocardial Infarction [TIMI] 
flow grade 0–2) in the left anterior descending 
coronary artery were randomized to receive either 
intracoronary tenecteplase (one fifth of the usual 
systemic dose according to weight) or abciximab 
(an intracoronary dose of 0.25 mg/kg followed by an 
intravenous infusion of 0.125 mcg/kg/min for 12 h). 
After crossing the culprit lesion with a guidewire, 
the study medication was infused through the guid-
ing catheter for 3 min. All patients had received 
oral acetylsalicylic acid (300 mg), clopidogrel 
(600 mg) and an intravenous bolus of 70 UI/kg 
of unfractionated heparin before the procedure. In 
both groups, PPCI was then performed as usual 
with implantation of coronary stents as needed. 
The complete study protocol was described in 
a previous publication [2].
All patients were scheduled for a contrast 
echocardiogram before discharge and at 6 months 
(contrast agent Sonovue, Bracco, The Nether-
lands), all of them performed with a GE Vivid 
7 ultrasound system by the same experienced 
cardiologist, who was blinded to the study medi-
cation, assessing the usual systolic and diastolic 
ventricular function parameters according to the 
American Society of Echocardiography. Addition-
ally, all patients were scheduled for a 4-month 
cardiac-magnetic resonance imaging (MRI) at an 
external radiological center, for a blinded analysis 
of infarct size, left ventricular volumes and ejection 
fraction, as previously described [2]. The study 
protocol was approved by the local and regional 
ethics committees. The trial was registered in 
Eudra CT (https://www.clinicaltrialregister.eu, 
identifier 2010-022725-16). All patients gave writ-
ten informed consent to participate in the study. 
From August 2012 to April 2016, 102 patients 
with acute anterior STEMI were screened for 
enrolment in the study, 26 of which were later ex-
cluded due to not meeting the listed criteria. Con-
sequently, 76 patients with acute anterior STEMI 
were randomized to receive either intracoronary 
tenecteplase (n = 38) or abciximab (n = 38) dur-
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ing PPCI. Both groups were comparable in demo-
graphic, clinical, angiographic and periprocedural 
characteristics, and there were no significant dif-
ferences in major cardiovascular or bleeding events 
between study groups, as published elsewhere [2].
Echocardiogram and cardio-MRI results are 
displayed in Table 1. Left ventricular volumes 
and ejection fraction did not significantly differ 
between the study groups at 6 months, and ad-
verse ventricular remodeling was similar. Only 
diastolic function, as assessed by the E/e’ ratio at 
6 months, was significantly better in the tenect-
eplase group (median 10.3 [interquartile range 8.1–
–14.6]) in comparison to the abciximab group (medi-
an 13.2 [interquartile range 10.7–15.5, respectively, 
p = 0.04]). An E/e’ ratio ≥ 13 was observed in 
26.6% of the patients in the tenecteplase group 
versus 51.4% in the abciximab group (p = 0.05) 
and final infarction size (expressed as weight of 
infarct mass in grams) had a significant correlation 
to e’ wave value (r = –0.49, p < 0.01) and E/e’ ratio 
(r = 0.45, p = 0.04).
Primary PCI is the strategy of choice in STEMI, 
and one of its main goals is saving as much myo-
cardium as possible, since impaired ventricular 
function after STEMI is an unfavorable prognostic 
predictor [3]. Adjunctive treatment with GPI during 
PPCI has shown to improve myocardial perfusion 
and reduce infarct size in some studies [1]. Ac-
cording to available research, the present study 
constitutes the first randomized trial comparing 
intracoronary administration of a fibrinolytic drug 
and a GPI in patients with STEMI undergoing 
PPCI. In a recent publication, it was communicated 
that there were no significant differences in infarct 
size between both drugs in the study population [2]. 
In the present manuscript, it is also reported that 
there were no significant differences in systolic 
ventricular function as well. There was only a mild 
trend to a better preservation of diastolic function 
in the tenecteplase group that could be considered 
as marginal.  
Previous [2] and the present results agree with 
those previously reported in the recent T-TIME 
Table 1. Echocardiogram and cardiac-magnetic resonance imaging (MRI) results.
i.c. Tenecteplase i.c. Abciximab P
48-hour echocardiogram N = 38 N = 38
LVEDV index [mL/m2] 54.2 [44.2–71.7] 51.5 [47.5–62.1] 0.69
LVESV index [mL/m2] 23.8 [14.9–35.5] 26.1 [18.1–36.7] 0.91
LVEF [%] 54.0 [40.2–66.7] 50.5 [43.0–60.7] 0.79
LAV index [mL/m2] 27.4 [22.6–37.4] 29.7 [23.6–33.2] 0.71
Average e’ wave [cm/s] 6.2 [5.0–7.7] 6.0 [4.7–7.0] 0.60
Average E/e’ ratio 11.4 [9.4–14.9] 14.3 [11.2–17.6] 0.04
Average E/e’ ratio ≥ 13 12 (33.3%) 21 (55.3%) 0.05
4-month angio-MRI N = 26 N = 28
LVEDV index [mL/m2] 85.4 [71.7–99.9] 88.5 [72.9–104.4] 0.94
LVESV index [ml/m2] 38.9 [25.0–54.0] 40.1 [31.2–55.8] 0.63
LVEF [%] 54.0 [44.0–62.0] 53.0 [44.5–59.5] 0.58
6-month echocardiogram N = 28 N = 35
LVEDV index [mL/m2] 54.8 [45.4–69.2] 55.4 [42.9–67.1] 0.82
LVESV index [mL/m2] 22.1 [13.5–33.9] 23.0 [13.3–31.9] 0.87
LVEF [%] 59.0 [47.0–73.0] 57.5 [43.0–60.7] 0.74
LV remodeling > 20% 6 (21.4%) 9 (26.5%) 0.65
LAV index [mL/m2] 28.3 [22.2–40.0] 28.8 [24.1–37.1] 0.75
Average e’ wave [cm/s] 6.5 [5.0–8.0] 6.0 [4.0–7.0] 0.23
E/e’ ratio 10.3 [8.1–14.6] 13.2 [10.7–15.5] 0.03
E/e’ ratio ≥ 13 8 (28.6%) 18 (51.4%) 0.05
Variables are expressed as median [interquartile range] or as n (%); LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular 
end-systolic volume; LVEF — left ventricular ejection fraction; LAV — left atrial volume; Average e’ wave — average of the values from the 
septal and lateral mitral annulus; Average E/e’ ratio — ratio of the transmitral Doppler E wave velocity and the composite mean of e’; LV — left 
ventricular
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study [4], in which intracoronary alteplase wors-
ened the microvascular obstruction and increased 
intramyocardial hemorrhage when compared to the 
placebo, essentially in case of prolonged ischemia. 
Furthermore, these worse results on myocardial 
reperfusion are not necessarily related to final 
infarct size, since edema and intramyocardial 
hemorrhage are usually solved when the 4-month 
monitoring MRI is performed. This could explain 
the absence of significant differences in infarct size 
between the two therapy groups. Additionally, as in 
the current study, in the T-TIME trial no significant 
benefits on ventricular function were found [4]. 
The sample size in this pilot study was ar-
bitrary and was not previously calculated. The 
relatively small size of infarcted myocardium in 
the whole study population could have limited the 
ability to detect significant differences in most 
systolic and diastolic function parameters. Addi-
tionally, comparing tenecteplase to an antiplatelet 
drug rather than a placebo may have diminished its 
capacity of showing positive results on the study 
endpoints. The choice of tenecteplase dose was se-
lected from previous case reports and observational 
studies, although it could have been insufficient to 
achieve the desirable antithrombotic effect. Finally, 
more recent P2Y12 inhibitors (such as ticagrelor 
or prasugrel) were not used in the present study 
since their administration is not recommended in 
addition to a fibrinolytic drug. 
In this first clinical randomized trial comparing 
intracoronary fibrinolysis with a GPI drug during 
PPCI, and when combining present results with 
those recently reported [2], no benefits were found 
on ventricular function nor infarct size after myo-
cardial infarction when intracoronary fibrinolysis 
was performed. Therefore, and lacking results 
from larger studies, the results do not support 
a systematic use of intracoronary fibrinolysis as 
adjunctive therapy during PPCI.
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